Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

University of Michigan Rogel Cancer Center

Status and phase

Terminated

Phase 1

Conditions

Waldenstrom Macroglobulinemia

Mantle Cell Lymphoma

Lymphoplasmacytic Lymphoma

Chronic Lymphocytic Leukemia

Lymphoma, T-Cell, Cutaneous

Lymphoma, T-Cell, Peripheral

Lymphoproliferative Disorders

Treatments

Drug: Pacritinib

Study type

Interventional

Funder types

Other

Identifiers

NCT03601819

UMCC 2018.048

HUM00144759 (Other Identifier)

Details and patient eligibility

About

This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.

Enrollment

4 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of any of the following:
1. Relapsed/refractory cutaneous (stage IIb-IV by ISCL/EORTC staging criteria) or peripheral T-cell lymphoma with progression after the last line of therapy and refractory to/intolerant of or have a contraindication to all established therapies known to provide clinical benefit (including brentuximab vedotin for patients with anaplastic large cell lymphomas) OR
2. Chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL), Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) or mantle cell lymphoma (MCL) with disease progression on ibrutinib or who discontinue ibrutinib due to toxicity/intolerance. In addition, patients should be refractory to/intolerant of or have a contraindication to all established therapies known to provide clinical benefit OR
3. Any lymphoproliferative disorder who have failed at least 2 prior therapies and are refractory to/intolerant of or have a contraindication to all established therapies known to provide clinical benefit and have had mutational analysis or sequencing studies performed in a CLIA certified laboratory demonstrating a mutation or gene fusion involving MyD88, JAK2, JAK3, TYK2, or IRAK1 that are known or suspected to be "activating" (gain-of-function).
Age ≥ 18 at time of enrollment
ECOG ≤ 2 (Eastern Cooperative Oncology Group scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 5 where 0 represents perfect health and 5 represents death.)
Adequate organ and marrow function as defined in the protocol
Ability to take oral medication without crushing, dissolving or chewing tablets.
In the investigator's opinion, the patient requires immediate treatment.
Ability to understand and the willingness to sign a written informed consent.
In the investigator's opinion, the patient has the ability to communicate satisfactorily with the investigator and the study team, to participate fully in the study, and comply with all requirements.

Exclusion criteria

History of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study
Pregnant or breast feeding women
Unwilling or unable to use a medically acceptable form of contraception during the time of participation in the trial (sexual abstinence is permissible) unless documented successful vasectomy, hysterectomy, bilateral oophorectomy or post-menopausal for at least 2 years
Uncontrolled current illness, including, but not limited to the following: Ongoing or active infections requiring intravenous antimicrobials; symptomatic congestive heart failure defined as NYHA class II, III or IV (Appendix II); unstable angina pectoris within 6 months of study enrollment; unstable cardiac arrhythmia; history of myocardial infarction, stroke or intracranial hemorrhage within 6 months prior to enrollment; moderate to severe hepatic impairment (Child-Pugh class B or C); psychiatric illness or social situations that would limit compliance with study requirements
Known HIV infection
Known positive Hepatitis B surface antigen or Hep C virus
Recent (within 21 days of initiation of therapy, day 1) major surgery
Less than 14 days have elapsed since last radiation therapy or chemotherapy treatment or patient has not recovered from all clinically significant treatment-related toxicity; less than 90 days have passed since date of autologous stem cell transplant and patient has not recovered to ≤grade 1 toxicity related to this procedure
Use of systemic steroids (oral, inhaled, nasal, topical) at a dose less > 10 mg/day of prednisone
Prior treatment with pacritinib
Uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP). Coombs positivity in absence of hemolysis is not an exclusion.
Requires anticoagulation with heparin, warfarin or equivalent Vit K antagonist
History of significant bleeding (≥Grade 2 by CTCAE) history or complications (including bleeding that may have occurred while on ibrutinib)
Hypersensitivity or allergic reaction to compounds related to pacritinib
Treatment with potent CYP450 inducers and strong CYP3A4 inhibitors for which no alternative is available; treatment with strong CYP450 inducers or strong CYP3A4 inhibitors within 2 weeks of initiation of therapy, day 1
Concurrent administration of QTc prolonging agents; significant QTc prolonging agents must be stopped within 5 half-lives of day 1.
Any gastrointestinal or metabolic condition that could interfere with the absorption of oral medication